Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GlaxoSmithKline granted Renaissance rights to market six approved dermatology drugs and three formulations of Zovirax acyclovir in the U.S. The dermatology products are Evoclin
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury